Information Provided By: 
Fly News Breaks for January 12, 2018
HZNP
Jan 12, 2018 | 08:54 EDT
As previously reported, Mizuho upgraded Horizon Pharma to Buy from Neutral and increased its price target to $18 from $12. Analyst Irina Koffler belies shares are poised for a positive move in 2018 driven by Krystexxa-related catalysts, sales growth, and the potential for further business development. Koffler raised his Krystexxa peak sales estimate to $750M and raised the terminal growth rate in his DCF to 2% from 0%.
News For HZNP From the Last 2 Days
There are no results for your query HZNP
